In the I-Box Biotech's New Rising Star ** Gener
Post# of 36568
(Total Views: 262)
Posted On: 07/15/2019 4:10:06 PM
In the I-Box Biotech's New Rising Star
** Generex A37 Immunotherapy Vaccine demonstrates high efficacy with low adverse side effects against many common cancers and diseases.
** Combination Phase II trial with MRK Keytruda and GNBT A37 for Breast Cancer enrolling 2019.
** Upfront license payments for AE37 by Shenzhen BioScien Pharmaceuticals for Prostate Cancer in China, Taiwan, Hong Kong and Macau.
** Proprietary buccal oral insulin delivery for $27 billion insulin market.
** Aggressive acquisition strategy of diagnostics, therapeutics, orthopedic surgical implants and patient care in play with recent closes and signed LOI’s.
** Plans to launch million bottles of CBD water and health products beginning 2019.
** Share price is low but in strong uptrend with near-term Nasdaq up-listing in sight.
Shares of Generex Biotechnology Corporation (OTC: GNBT) have been rising and continue in a strong uptrend for several reasons. Unlike many biotech companies that are developing just one technology and have only one drug or very few drugs in their pipeline, Generex is successfully executing an aggressive acquisition strategy to own a broad spectrum of diagnostic products, therapeutic products, orthopedic implants, surgical kits, biologic products, and care delivery solutions through their MSO.
** Generex A37 Immunotherapy Vaccine demonstrates high efficacy with low adverse side effects against many common cancers and diseases.
** Combination Phase II trial with MRK Keytruda and GNBT A37 for Breast Cancer enrolling 2019.
** Upfront license payments for AE37 by Shenzhen BioScien Pharmaceuticals for Prostate Cancer in China, Taiwan, Hong Kong and Macau.
** Proprietary buccal oral insulin delivery for $27 billion insulin market.
** Aggressive acquisition strategy of diagnostics, therapeutics, orthopedic surgical implants and patient care in play with recent closes and signed LOI’s.
** Plans to launch million bottles of CBD water and health products beginning 2019.
** Share price is low but in strong uptrend with near-term Nasdaq up-listing in sight.
Shares of Generex Biotechnology Corporation (OTC: GNBT) have been rising and continue in a strong uptrend for several reasons. Unlike many biotech companies that are developing just one technology and have only one drug or very few drugs in their pipeline, Generex is successfully executing an aggressive acquisition strategy to own a broad spectrum of diagnostic products, therapeutic products, orthopedic implants, surgical kits, biologic products, and care delivery solutions through their MSO.
(0)
(0)